Leading the Way in Precision Medicine
An innovative company with deep scientific and clinical expertise, dedicated to developing precision oncology medicines that deliver the best outcomes for patients.
Anbogen Therapeutics is a clinical-stage biotech company dedicated to designing and developing precision oncology therapies to improve patients' lives. Founded by a group of exceptional scientists from the National Health Research Institute, the most prestigious medical research institute in Taiwan, we are committed to bridging the gap between research and clinical development. Our mission is to create breakthrough science that transforms the lives of cancer patients.
Milestones
2023.07
In July 2023, ABT-101 obtained the first crystal form patent in Taiwan
2023.06
In June 2023, Anbogen filed a US provisional application for the crystal form of ABT-301
2023.02
In February 2023, the US FDA formally approved the amendment to the Investigational New Drug (IND) clinical trial plan for ABT-101
2022.09
In September 2022, the first patient was recruited for the ABT-101 clinical trial
2022.08
In August 2022, Anbogen's laboratory, located in the National Biotechnology Research Park, was officially inaugurated
2022.03
In March 2022, the TFDA approved the phase 1b/2 clinical trial of ABT-101 in Taiwan
2020.10
In October 2020, Anbogen signed a license agreement for ABT-301 with Taipei Medical University
2020.04
In April 2020, Anbogen signed a license agreement for ABT-101 with the National Health Research Institutes
2019.04
Dr. Chuan Shih, Dr. Hsing-Pang Hsieh, and Dr. Tsu-An Hsu founded Anbogen Therapeutics, Inc.